WASHINGTON, D.C. — January 13, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Kenneth Kelley, M.B.A., and Jordan Orange, M.D., Ph.D., to its Board of Trustees. Mr. Kelley is a Harvard Senior Advanced Leadership Fellow, focusing on global health, biosecurity and the market inefficiency leading to a lack of vaccines against neglected tropical diseases (NTDs) and emerging pandemic threats. Dr. Orange is chief of Immunology, Allergy and Rheumatology, and professor and section head for Immunology, Allergy and Rheumatology in the pediatrics department at Baylor College of Medicine.
January 11, 2016
WASHINGTON, D.C. — January 5, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the Board of Trustees unanimously appointed Axel Hoos, M.D., Ph.D., to serve as chairman of the board, and Peter L. Thoren to serve as vice chairman. Both were appointed to interim positions in December 2014.
WASHINGTON, D.C. — November 16, 2015 — The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today signed a project agreement with King Saud University to build vaccine research and development capacity in the Middle East and North Africa (MENA) region and advance the establishment of a vaccine research institute in Saudi Arabia.
October 23, 2015
The Washington Post
WASHINGTON, D.C., BANGALORE, AMSTERDAM — October 14, 2015 — The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs). The European Union, through its EuropeAid program, recently awarded a five-year grant of €333,000 to AIGHD to establish this EU-India partnership.
October 6, 2015
The Associated Press